Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 17

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 17
---
ger Agreement?

A:Yes. On November 20, 2025, TELI’s stockholders adopted the Merger Agreement and approved the Merger and the other Contemplated Transactions via the TELI Stockholder Written Consent (as defined below). For more information on the matters approved by the stockholders of TELI please see the sections titled “ The Merger Agreement—Conditions to the Merger.”

Q: Who can help answer my questions?

A:If you are a holder of TELO Common Stock as of the record date and would like additional copies, without charge, of this proxy statement or if you have questions about the Merger, including the procedures for voting your shares, you should contact TELO at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida, (786) 396-6723.

| 7 |

<div align='center'>SUMMARY OF MERGER PROPOSAL</div>

This summary highlights selected information from this proxy statement and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the TELO Annual Meeting, you should read this entire proxy statement carefully, including the Merger Agreement attached as Annex A, the valuation report of TELI Pharmaceuticals, Inc. attached as Annex B, the valuation report for TELO Pharmaceuticals Inc. is attached as Annex C, the fairness opinion for the Merger is attached as Annex D and the Telomir-1 License Agreement is attached as Annex E. For more information, please see the section titled “Where You Can Find More Information” beginning on page 77 of this proxy statement.

The Companies

Telomir Pharmaceuticals, Inc.

100 SE 2nd St, Suite 2000, #1009, Miami, Florida

(786) 396-6723

TELO, a pre-clinical biotechnology company, is the exclusive licensor of Telomir-1 in the United States. Telomir-1 is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and Age-related Mac